PI(3)King the Right Target
PI(3)King the right target after CDK4/6 inhibitors fail patients is an exciting area of research and FDA approval. Now that there are multiple options approved by the FDA and more to come, patients have more treatment choices. Join host Abigail Johnston as she interviews 2 patients who give us their perspective on these advances, as well as a doctor whose scientific research has led the way identifying PIK3CA mutations as a cancer genomic biomarker.
Roberta Lombardi and Infinite Strength
Roberta Lombardi wanted to do something for the Connecticut moms and kids with breast cancer, but that *something* quickly morphed into a nonprofit effort to help break through barriers in the lives of moms with MBC. Laser focused on single moms with kids under 19 living at home and financial need, Roberta took her nonprofit (she calls it her fourth child) nationwide in mid-2023 and is already serving women in 27 states. While providing 6 months of financial support to approved applicants remains the core of Infinite Strength, Roberta has added to the support through one-day local (Connecticut) mom-and-kid retreats, in-person and online panels with some of the best experts in cancer care, a 2024 MBC conference, and a groundbreaking effort to change the picture through the Connecticut Coalition of Oncologists. This is a woman who does not sit still and we are so lucky to have her as an ally for people living with MBC. This episode may inspire *you* to get out there and do something!